Drug Trial Radar · NCT06805305
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
Last checked: Nov 19, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Mar 17, 2025
Primary completion
Mar 2030
Study completion Mar 2032
Sponsor
- Lead sponsor
- Diakonos Oncology CorporationIndustry
- Sponsor type
- Industry
- First posted
- Feb 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if DOC1021 + pIFN alongside standard of care (SOC) will improve survival in adult patients newly diagnosed with glioblastoma (IDH-wt). It will also evaluate the safety of DOC1021 + pIFN. Researchers will compare DOC1021 dendritic cell immunotherapy regimen added to SOC compared to SOC treatment alone. Participants in the DOC1021 + pIFN + SOC arm will: * Take filgrastim subcutaneously x 5 doses and subsequently undergo a leukapheresis collection * Undergo ultrasound guided perinodal DOC1021 injections every 2 weeks for a total of 3 doses * Receive subcutaneous pIFN injections weekly for a total of 6 doses in parallel with the DOC1021 injections Both arms of the trial will: \- Visit the clinic regularly to assess quality of life, symptoms, medication use, imaging, bloodwork, and to receive SOC treatment with surgery, temozolomide chemotherapy and radiation
Conditions
- Glioblastoma (GBM)
Interventions
DOC1021Biological
Double-loaded dendritic cell vaccine, loaded with tumor lysate and mRNA using proprietary method
Tumor resectionProcedure
SOC brain tumor resection
Temodar (Temozolomide)Drug
SOC concomitant temozolomide during radiation and adjuvant temozolomide after radiation
SOC cranial radiationRadiation
60Gy radiation over 6 weeks in 2Gy fractions
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (time in months from randomization until death for each participant)Time frame: 5 years
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona · Active not recruiting
City of Hope
Duarte, California · Recruiting
HOAG
Newport Beach, California · Recruiting
UCSF
San Francisco, California · Recruiting
Baptist MD Anderson Cancer Center
Jacksonville, Florida · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Cooper University Health Care
Camden, New Jersey · Recruiting
Rutgers Cancer Institute
New Brunswick, New Jersey · Recruiting
Atlantic Health
Summit, New Jersey · Recruiting
Lenox Hill Hospital
New York, New York · Recruiting
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina · Recruiting
Wake Forest University Health Sciences
Winston-Salem, North Carolina · Recruiting
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio · Recruiting
UPMC Presbyterian Hospital
Pittsburgh, Pennsylvania · Recruiting
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee · Recruiting
UTHealth Houston
Houston, Texas · Recruiting
Baylor College of Medicine
Houston, Texas · Recruiting
The University of Texas Health Science Center at San Antonio
San Antonio, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.